Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
$1.36
$1.25
$11.80
$2.54M2.37127,289 shs23,000 shs
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$0.00
$0.00
$0.00
$6K1.6183,499 shsN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
$2.31
-56.7%
$7.32
$2.00
$11.64
$122.50M1.55703,597 shs32.68 million shs
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
$2.52
+0.8%
$2.53
$0.82
$3.38
$90.94M1.141.76 million shs1.11 million shs
Vaxart, Inc. stock logo
VXRT
Vaxart
$0.45
-8.6%
$0.47
$0.29
$1.07
$112.90M1.262.44 million shs2.69 million shs
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00%0.00%0.00%0.00%+150.00%
INmune Bio, Inc. stock logo
INMB
INmune Bio
-56.66%-62.86%-69.03%-69.57%-73.81%
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
+0.80%+6.78%-2.33%+69.13%+147.06%
Vaxart, Inc. stock logo
VXRT
Vaxart
-8.59%-19.34%+3.48%+21.34%-32.26%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
2.0354 of 5 stars
3.60.00.00.02.81.70.6
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
1.999 of 5 stars
3.52.00.00.02.60.00.6
Vaxart, Inc. stock logo
VXRT
Vaxart
2.3382 of 5 stars
3.51.00.00.03.01.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
0.00
N/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.00
N/AN/AN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
2.71
Moderate Buy$22.80887.01% Upside
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
3.00
Buy$9.00257.14% Upside
Vaxart, Inc. stock logo
VXRT
Vaxart
3.00
Buy$3.00563.72% Upside

Current Analyst Ratings Breakdown

Latest INMB, GNCA, MBOT, VXRT, and BVXV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
7/1/2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Outperform ➝ Sector Underperform
4/10/2025
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
N/AN/AN/AN/A($3.81) per shareN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
$1.91M0.00N/AN/A$0.47 per share0.00
INmune Bio, Inc. stock logo
INMB
INmune Bio
$10K5,308.38N/AN/A$1.45 per share1.59
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
N/AN/AN/AN/A$0.17 per shareN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
$28.70M3.60N/AN/A$0.26 per share1.74
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
-$5.80M-$2.55N/AN/AN/AN/A-346.36%-29.52%N/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
-$33.20M-$0.61N/AN/AN/AN/A-182.88%-62.76%N/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$42.08M-$1.93N/AN/AN/AN/A-119.35%-89.37%7/30/2025 (Estimated)
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
-$11.44M-$0.65N/AN/AN/AN/A-110.27%-94.20%8/13/2025 (Estimated)
Vaxart, Inc. stock logo
VXRT
Vaxart
-$66.95M-$0.27N/AN/AN/A-122.63%-91.89%-38.40%8/14/2025 (Estimated)

Latest INMB, GNCA, MBOT, VXRT, and BVXV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q1 2025
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
-$0.15-$0.08+$0.07-$0.08N/AN/A
5/13/2025Q1 2025
Vaxart, Inc. stock logo
VXRT
Vaxart
-$0.07-$0.07N/A-$0.07$2.85 million$20.88 million
5/8/2025Q1 2025
INmune Bio, Inc. stock logo
INMB
INmune Bio
-$0.43-$0.43N/A-$0.43N/A$0.05 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
N/AN/AN/AN/AN/A
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
N/AN/AN/AN/AN/A
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/AN/AN/AN/AN/A
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
N/AN/AN/AN/AN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
N/A
4.12
4.12
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.24
1.35
1.35
INmune Bio, Inc. stock logo
INMB
INmune Bio
N/A
2.64
2.64
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
N/A
16.19
16.19
Vaxart, Inc. stock logo
VXRT
Vaxart
N/A
0.64
0.64

Institutional Ownership

CompanyInstitutional Ownership
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
11.83%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
0.64%
INmune Bio, Inc. stock logo
INMB
INmune Bio
12.72%
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
16.30%
Vaxart, Inc. stock logo
VXRT
Vaxart
18.05%

Insider Ownership

CompanyInsider Ownership
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
6.03%
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
1.61%
INmune Bio, Inc. stock logo
INMB
INmune Bio
35.70%
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
4.74%
Vaxart, Inc. stock logo
VXRT
Vaxart
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
BiondVax Pharmaceuticals Ltd. stock logo
BVXV
BiondVax Pharmaceuticals
331.87 million1.76 millionNot Optionable
Genocea Biosciences, Inc. stock logo
GNCA
Genocea Biosciences
7058.73 million57.79 millionNot Optionable
INmune Bio, Inc. stock logo
INMB
INmune Bio
1022.98 million14.78 millionOptionable
Microbot Medical Inc. stock logo
MBOT
Microbot Medical
2036.38 million34.65 millionOptionable
Vaxart, Inc. stock logo
VXRT
Vaxart
120228.31 million222.37 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BiondVax Pharmaceuticals stock logo

BiondVax Pharmaceuticals NASDAQ:BVXV

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Genocea Biosciences stock logo

Genocea Biosciences NASDAQ:GNCA

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

INmune Bio stock logo

INmune Bio NASDAQ:INMB

$2.31 -3.02 (-56.66%)
Closing price 06/30/2025 04:00 PM Eastern
Extended Trading
$2.11 -0.20 (-8.66%)
As of 09:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Microbot Medical stock logo

Microbot Medical NASDAQ:MBOT

$2.52 +0.02 (+0.80%)
Closing price 06/30/2025 04:00 PM Eastern
Extended Trading
$2.52 0.00 (-0.20%)
As of 09:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.

Vaxart stock logo

Vaxart NASDAQ:VXRT

$0.45 -0.04 (-8.59%)
Closing price 06/30/2025 04:00 PM Eastern
Extended Trading
$0.48 +0.03 (+7.30%)
As of 09:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.